APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense oligonucleotides (ASO) Drug and siRNA Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Growth and Trends Forecast to 2032

23 December 2025120 pages

Choose your research edition.

Industry ResearchAntisense oligonucleotides (ASO) Drug and siRNA Drug Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

According to APO Research, the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense oligonucleotides (ASO) Drug and siRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Antisense oligonucleotides (ASO) Drug and siRNA Drug market include Novartis, Novo Nordisk, Biogen, AstraZeneca, WAVElife, Therapeutics, The WhiteOak Group, Inc., Sylentis and Sirnaomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antisense oligonucleotides (ASO) Drug and siRNA Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antisense oligonucleotides (ASO) Drug and siRNA Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Company

Novartis

Novo Nordisk

Biogen

AstraZeneca

WAVElife

Therapeutics

The WhiteOak Group, Inc.

Sylentis

Sirnaomics

Silence

Secarna

Sarepta Therapeutics

Quark Pharmaceuticals

ProQR

Miragen Therapeutics

Ionis

Genzyme

Exicure

Dicerna

Avidity Biosciences

Arrowhead

Alnylam

Akcea

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type

Antisense Oligonucleotides (ASO) Drug

siRNA Drug

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application

Chronic Liver Disease

Protein Deposition Disease

Single Gene Rare Disease

Others

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense oligonucleotides (ASO) Drug and siRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense oligonucleotides (ASO) Drug and siRNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2021-2026) Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2027-2032) Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2026) Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2026) Table 24. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends Table 37. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers Table 38. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges Table 39. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints Table 40. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Company (2021-2026) Table 42. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Company Headquarters & Area Served Table 44. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company, Product Type & Application Table 45. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 52. Novartis Recent Development Table 53. Novo Nordisk Company Information Table 54. Novo Nordisk Business Overview Table 55. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 57. Novo Nordisk Recent Development Table 58. Biogen Company Information Table 59. Biogen Business Overview Table 60. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 62. Biogen Recent Development Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 67. AstraZeneca Recent Development Table 68. WAVElife Company Information Table 69. WAVElife Business Overview Table 70. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 72. WAVElife Recent Development Table 73. Therapeutics Company Information Table 74. Therapeutics Business Overview Table 75. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 77. Therapeutics Recent Development Table 78. The WhiteOak Group, Inc. Company Information Table 79. The WhiteOak Group, Inc. Business Overview Table 80. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 82. The WhiteOak Group, Inc. Recent Development Table 83. Sylentis Company Information Table 84. Sylentis Business Overview Table 85. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 87. Sylentis Recent Development Table 88. Sirnaomics Company Information Table 89. Sirnaomics Business Overview Table 90. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 92. Sirnaomics Recent Development Table 93. Silence Company Information Table 94. Silence Business Overview Table 95. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 97. Silence Recent Development Table 98. Secarna Company Information Table 99. Secarna Business Overview Table 100. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 102. Secarna Recent Development Table 103. Sarepta Therapeutics Company Information Table 104. Sarepta Therapeutics Business Overview Table 105. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 107. Sarepta Therapeutics Recent Development Table 108. Quark Pharmaceuticals Company Information Table 109. Quark Pharmaceuticals Business Overview Table 110. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 112. Quark Pharmaceuticals Recent Development Table 113. ProQR Company Information Table 114. ProQR Business Overview Table 115. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 117. ProQR Recent Development Table 118. Miragen Therapeutics Company Information Table 119. Miragen Therapeutics Business Overview Table 120. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 122. Miragen Therapeutics Recent Development Table 123. Ionis Company Information Table 124. Ionis Business Overview Table 125. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 127. Ionis Recent Development Table 128. Genzyme Company Information Table 129. Genzyme Business Overview Table 130. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 132. Genzyme Recent Development Table 133. Exicure Company Information Table 134. Exicure Business Overview Table 135. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 137. Exicure Recent Development Table 138. Dicerna Company Information Table 139. Dicerna Business Overview Table 140. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 142. Dicerna Recent Development Table 143. Avidity Biosciences Company Information Table 144. Avidity Biosciences Business Overview Table 145. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 147. Avidity Biosciences Recent Development Table 148. Arrowhead Company Information Table 149. Arrowhead Business Overview Table 150. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 152. Arrowhead Recent Development Table 153. Alnylam Company Information Table 154. Alnylam Business Overview Table 155. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 157. Alnylam Recent Development Table 158. Akcea Company Information Table 159. Akcea Business Overview Table 160. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 161. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 162. Akcea Recent Development Table 163. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2026) Table 166. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Country (2027-2032) Table 168. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2026) Table 171. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2026) Table 176. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Country (2027-2032) Table 178. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 180. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2026) Table 181. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Country (2027-2032) Table 183. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 185. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2026) Table 186. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share Forecast by Country (2027-2032) Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Image Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2021-2032) Figure 7. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Antisense Oligonucleotides (ASO) Drug Image Figure 13. Global Antisense Oligonucleotides (ASO) Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. siRNA Drug Image Figure 15. Global siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type 2025 VS 2032 Figure 18. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2032) Figure 19. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2032) Figure 21. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Type (2021-2032) Figure 23. Chronic Liver Disease Image Figure 24. Global Chronic Liver Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Protein Deposition Disease Image Figure 26. Global Protein Deposition Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Single Gene Rare Disease Image Figure 28. Global Single Gene Rare Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Others Image Figure 30. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application 2025 VS 2032 Figure 33. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2032) Figure 34. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2032) Figure 36. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 43. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 46. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 49. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 52. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotides (ASO) Drug
  • siRNA Drug
Applications
  • Chronic Liver Disease
  • Protein Deposition Disease
  • Single Gene Rare Disease
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Biogen
  • AstraZeneca
  • WAVElife
  • Therapeutics
  • The WhiteOak Group, Inc.
  • Sylentis
  • Sirnaomics
  • Silence
  • Secarna
  • Sarepta Therapeutics
  • Quark Pharmaceuticals
  • ProQR
  • Miragen Therapeutics
  • Ionis
  • Genzyme
  • Exicure
  • Dicerna
  • Avidity Biosciences
  • Arrowhead
  • Alnylam
  • Akcea

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  8. 1.5.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (2021-2032)
2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Antisense Oligonucleotides (ASO) Drug
  3. 2.1.2 siRNA Drug
  4. 2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type
  5. 2.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Regions
  9. 2.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Type (2021-2026)
3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Chronic Liver Disease
  3. 3.1.2 Protein Deposition Disease
  4. 3.1.3 Single Gene Rare Disease
  5. 3.1.4 Others
  6. 3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application
  7. 3.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Regions
  11. 3.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
  2. 4.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers
  3. 4.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges
  4. 4.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (2021-2026)
  2. 5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Key Company Headquarters & Area Served
  4. 5.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company, Product Type & Application
  5. 5.5 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Antisense oligonucleotides (ASO) Drug and siRNA Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Novo Nordisk
  8. 6.2.1 Novo Nordisk Company Information
  9. 6.2.2 Novo Nordisk Business Overview
  10. 6.2.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  12. 6.2.5 Novo Nordisk Recent Developments
  13. 6.3 Biogen
  14. 6.3.1 Biogen Company Information
  15. 6.3.2 Biogen Business Overview
  16. 6.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  18. 6.3.5 Biogen Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 WAVElife
  26. 6.5.1 WAVElife Company Information
  27. 6.5.2 WAVElife Business Overview
  28. 6.5.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  30. 6.5.5 WAVElife Recent Developments
  31. 6.6 Therapeutics
  32. 6.6.1 Therapeutics Company Information
  33. 6.6.2 Therapeutics Business Overview
  34. 6.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  36. 6.6.5 Therapeutics Recent Developments
  37. 6.7 The WhiteOak Group, Inc.
  38. 6.7.1 The WhiteOak Group, Inc. Company Information
  39. 6.7.2 The WhiteOak Group, Inc. Business Overview
  40. 6.7.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  42. 6.7.5 The WhiteOak Group, Inc. Recent Developments
  43. 6.8 Sylentis
  44. 6.8.1 Sylentis Company Information
  45. 6.8.2 Sylentis Business Overview
  46. 6.8.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  48. 6.8.5 Sylentis Recent Developments
  49. 6.9 Sirnaomics
  50. 6.9.1 Sirnaomics Company Information
  51. 6.9.2 Sirnaomics Business Overview
  52. 6.9.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  54. 6.9.5 Sirnaomics Recent Developments
  55. 6.10 Silence
  56. 6.10.1 Silence Company Information
  57. 6.10.2 Silence Business Overview
  58. 6.10.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  60. 6.10.5 Silence Recent Developments
  61. 6.11 Secarna
  62. 6.11.1 Secarna Company Information
  63. 6.11.2 Secarna Business Overview
  64. 6.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  66. 6.11.5 Secarna Recent Developments
  67. 6.12 Sarepta Therapeutics
  68. 6.12.1 Sarepta Therapeutics Company Information
  69. 6.12.2 Sarepta Therapeutics Business Overview
  70. 6.12.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  72. 6.12.5 Sarepta Therapeutics Recent Developments
  73. 6.13 Quark Pharmaceuticals
  74. 6.13.1 Quark Pharmaceuticals Company Information
  75. 6.13.2 Quark Pharmaceuticals Business Overview
  76. 6.13.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  78. 6.13.5 Quark Pharmaceuticals Recent Developments
  79. 6.14 ProQR
  80. 6.14.1 ProQR Company Information
  81. 6.14.2 ProQR Business Overview
  82. 6.14.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  84. 6.14.5 ProQR Recent Developments
  85. 6.15 Miragen Therapeutics
  86. 6.15.1 Miragen Therapeutics Company Information
  87. 6.15.2 Miragen Therapeutics Business Overview
  88. 6.15.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  90. 6.15.5 Miragen Therapeutics Recent Developments
  91. 6.16 Ionis
  92. 6.16.1 Ionis Company Information
  93. 6.16.2 Ionis Business Overview
  94. 6.16.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  96. 6.16.5 Ionis Recent Developments
  97. 6.17 Genzyme
  98. 6.17.1 Genzyme Company Information
  99. 6.17.2 Genzyme Business Overview
  100. 6.17.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  102. 6.17.5 Genzyme Recent Developments
  103. 6.18 Exicure
  104. 6.18.1 Exicure Company Information
  105. 6.18.2 Exicure Business Overview
  106. 6.18.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  108. 6.18.5 Exicure Recent Developments
  109. 6.19 Dicerna
  110. 6.19.1 Dicerna Company Information
  111. 6.19.2 Dicerna Business Overview
  112. 6.19.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  114. 6.19.5 Dicerna Recent Developments
  115. 6.20 Avidity Biosciences
  116. 6.20.1 Avidity Biosciences Company Information
  117. 6.20.2 Avidity Biosciences Business Overview
  118. 6.20.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  120. 6.20.5 Avidity Biosciences Recent Developments
  121. 6.21 Arrowhead
  122. 6.21.1 Arrowhead Company Information
  123. 6.21.2 Arrowhead Business Overview
  124. 6.21.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  126. 6.21.5 Arrowhead Recent Developments
  127. 6.22 Alnylam
  128. 6.22.1 Alnylam Company Information
  129. 6.22.2 Alnylam Business Overview
  130. 6.22.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  132. 6.22.5 Alnylam Recent Developments
  133. 6.23 Akcea
  134. 6.23.1 Akcea Company Information
  135. 6.23.2 Akcea Business Overview
  136. 6.23.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue, Global Share and Gross Margin (2021-2026)
  137. 6.23.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  138. 6.23.5 Akcea Recent Developments
7 North America
  1. 7.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  3. 7.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  3. 10.3 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst